BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 9733874)

  • 1. Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4(+) T cells.
    Chen M; Shirai M; Liu Z; Arichi T; Takahashi H; Nishioka M
    J Virol; 1998 Oct; 72(10):8301-8. PubMed ID: 9733874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways.
    Lee SP; Wallace LE; Mackett M; Arrand JR; Searle PF; Rowe M; Rickinson AB
    Int Immunol; 1993 May; 5(5):451-60. PubMed ID: 8391306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
    Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
    Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Epstein-Barr virus-transformed, autologous B-lymphoblastoid cells as antigen-presenting cells for establishment and maintenance of dengue virus-specific, human cytotoxic T lymphocyte clones.
    Livingston PG; Kurane I; Ennis FA
    J Virol Methods; 1997 Aug; 67(1):77-84. PubMed ID: 9274820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presentation of Candida albicans and purified protein derivative soluble antigens by Epstein-Barr virus-transformed human lymphoblastoid B-cell lines.
    Reitnauer PJ; Brown LR; Hank JA; Sondel PM
    Cell Immunol; 1986 Apr; 99(1):196-208. PubMed ID: 3019572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of tetraspanin CD63 in antigen presentation via MHC class II.
    Petersen SH; Odintsova E; Haigh TA; Rickinson AB; Taylor GS; Berditchevski F
    Eur J Immunol; 2011 Sep; 41(9):2556-61. PubMed ID: 21660937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition of endogenously synthesized HLA-DR4 restricted HCV epitopes presented by autologous EBV transformed B-lymphoblastoid cell line.
    Yang M; Zhu F; Sønderstrup G; Eckels DD
    Vaccine; 2005 Jan; 23(7):951-62. PubMed ID: 15603898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential recognition of tumor-derived and in vitro Epstein-Barr virus-transformed B-cell lines by fetal calf serum-specific T4-positive cytotoxic T-lymphocyte clones.
    Torsteinsdottir S; Masucci MG; Brautbar C; Lenoir G; Klein G; Klein E
    Cell Immunol; 1986 Apr; 98(2):453-66. PubMed ID: 3019570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells.
    Hatakeyama N; Tamura Y; Sahara H; Suzuki N; Suzuki K; Hori T; Mizue N; Torigoe T; Tsutsumi H; Sato N
    Exp Hematol; 2006 Feb; 34(2):197-207. PubMed ID: 16459188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous B lymphoblastoid cell lines and long-term cultured T cells as stimulators in the mixed lymphocyte reaction: analysis of the role of HLA class II antigens as stimulatory molecules.
    Santoli D; Radka SF; Igarashi M; Kreider BL; Ferrone S
    J Immunol; 1986 Jul; 137(2):400-7. PubMed ID: 2941479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.
    Tischer-Zimmermann S; Bonifacius A; Santamorena MM; Mausberg P; Stoll S; Döring M; Kalinke U; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
    Front Immunol; 2023; 14():878953. PubMed ID: 37033971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1.
    Landais E; Saulquin X; Scotet E; Trautmann L; Peyrat MA; Yates JL; Kwok WW; Bonneville M; Houssaint E
    Blood; 2004 Feb; 103(4):1408-16. PubMed ID: 14563644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid cells formed by fusion of Epstein-Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro.
    Cywinski AL; Dunnion DJ; Teobald I; Tucker VC; Browning MJ
    Tissue Antigens; 2006 Aug; 68(2):115-26. PubMed ID: 16866881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells.
    Long HM; Zuo J; Leese AM; Gudgeon NH; Jia H; Taylor GS; Rickinson AB
    Blood; 2009 Jul; 114(4):807-15. PubMed ID: 19443664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
    Ramadan G
    Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of minor histocompatibility antigen-specific T-helper but not T-cytotoxic response is dependent on the source of antigen-presenting cell.
    van Els CA; Bakker A; van Rood JJ; Goulmy E
    Hum Immunol; 1990 May; 28(1):39-50. PubMed ID: 2160446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential antigen presentation by heat-treated peripheral blood mononuclear cells and Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCL): heated EBV-LCL present alloantigen and soluble antigen but are deficient in the stimulation of autologous EBV-LCL primed T cells.
    Mandell RB; Hank JA; Chen BP; Robins HI; Sondel PM
    Hum Immunol; 1987 Jul; 19(3):163-77. PubMed ID: 3040644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients.
    Hauber I; Gulle H; Wolf HM; Maris M; Eggenbauer H; Eibl MM
    J Exp Med; 1995 Apr; 181(4):1411-23. PubMed ID: 7699327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alloantigen presentation by B cells: analysis of the requirement for B-cell activation.
    Wilson JL; Cunningham AC; Kirby JA
    Immunology; 1995 Nov; 86(3):325-30. PubMed ID: 8550066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.
    Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O
    Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.